#VentureCapital is flowing again into #biotech, but the slower pace of investments can impact the ways CEOs are being compensated. CEO & Managing Partner Leslie Loveless offers her perspectives on the topic in this insightful new article in BioSpace. She explains that pay packages and one’s appetite for risk help determine whether a CEO candidate is right for the job. “There are a lot of people that are very drawn to the higher-risk, higher-reward scenario that you see in biotech, and if that is what you’re drawn to, great. Go for it,” Loveless said. “But if that is not how you are wired, if that’s not in your DNA, then I would encourage folks to appreciate that about themselves. And don’t go into a negotiation with a biotech wanting them to pay you like they are Big Pharma, because they’re not going to. That’s not how they’re wired.” We appreciate the coverage, Angela Gabriel! #lifesciences #executivesearch
Thanks for sharing
Content Manager (Life Sciences Careers) at BioSpace
1moI so appreciate Leslie Loveless's expertise and insights for this article!